Opthea Ltd — Major Shareholding Notification 2019

Aug 28, 2019

==> picture [508 x 648] intentionally omitted <==

----- Start of picture text -----

Form 604
Corporations Act 2001
Section 671B
Notice of change of interests of substantial holder
To Company Name/Scheme Opthea Limited
ACN/ARSN 006 340 567
1. Details of substantial holder (1)
Name BVF Partners LP on its own behalf and on behalf of BVF Inc. and Mark N. Lampert
ACN/ARSN (if applicable)
There was a change in the interests of the
substantial holder on:
20/08/2019; 27/08/2019
The previous notice was given to the company on 19/08/2019
The previous notice was dated 16/08/2019
2. Previous and present voting power
The total number of votes attached to all the voting shares in the company or voting interests in the scheme that the substantial holder or an associate (2) had a
relevant interest (3) in when last required, and when now required, to give a substantial holding notice to the company or scheme, are as follows:
Previous notice Present notice
Class of securities (4)
Person’s votes Voting power (5) Person’s votes Voting power (5)
Fully Paid Ordinary Shares 23,605,918 9.45% 13,105,918 5.25%
3. Changes in relevant interests
Particulars of each change in, or change in the nature of, a relevant interest of the substantial holder or an associate in voting securities of the company or
scheme, since the substantial holder was last required to give a substantial holding notice to the company or scheme are as follows:
Class and
Person whose Consideration
Date of Nature of number of Person’s votes
change relevant interest change (6) given in relation securities affected
changed to change (7) affected
BVF Partners LP, BVF On Market sale of fully
20/08/2019 Inc. and Mark N. Lampert, and Biotechnology Value paid ordinary shares AUD 632,861.55 248,181 fully paid 248,181
Fund, LP ordinary shares
BVF Partners, L.P., BVF On Market sale of fully
20/08/2019 Inc. and Mark N. Lampert, and Biotechnology Value paid ordinary shares AUD 513,562.35 201,397 fully paid 201,397
Fund II L.P. ordinary shares
BVF Partners, L.P., BVF On Market sale of fully
paid ordinary shares 36,710 fully paid
Inc. and Mark N. Lampert,
20/08/2019 BVF Partners OS, Ltd., AUD 93,610.50 ordinary shares 36,710
and Biotechnology Value
Trading Fund OS, L.P.
On Market sale of fully
BVF Partners LP, BVF paid ordinary shares 13,712 fully paid
20/08/2019 Inc. and Mark N. Lampert, AUD 34,965.60 ordinary shares 13,712
and MSI BVF SPV, LLC
----- End of picture text -----

Date of change	Person whose relevant interest changed	Nature of change (6)	Consideration given in relation to change (7)	Class and number of securities affected	Person’s votes affected
20/08/2019	BVF Partners LP, BVF Inc. and Mark N. Lampert, and Biotechnology Value Fund, LP	On Market sale of fully paid ordinary shares	AUD 632,861.55	248,181 fully paid ordinary shares	248,181
20/08/2019	BVF Partners, L.P., BVF Inc. and Mark N. Lampert, and Biotechnology Value Fund II L.P.	On Market sale of fully paid ordinary shares	AUD 513,562.35	201,397 fully paid ordinary shares	201,397
20/08/2019	BVF Partners, L.P., BVF Inc. and Mark N. Lampert, BVF Partners OS, Ltd., and Biotechnology Value Trading Fund OS, L.P.	On Market sale of fully paid ordinary shares	AUD 93,610.50	36,710 fully paid ordinary shares	36,710
20/08/2019	BVF Partners LP, BVF Inc. and Mark N. Lampert, and MSI BVF SPV, LLC	On Market sale of fully paid ordinary shares	AUD 34,965.60	13,712 fully paid ordinary shares	13,712
27/08/2019	BVF Partners LP, BVF Inc. and Mark N. Lampert, and Biotechnology Value Fund, LP	On Market sale of fully paid ordinary shares	AUD 13,347,028.80	4,943,344 fully paid ordinary shares	4,943,344

27/08/2019 I	BVF Partners, L.P., BVF nc. and Mark N. Lampert, and Biotechnology Value Fund II L.P.	On Market sale of fully paid ordinary shares	AUD 10,856,916.00	4,021,080 fully paid ordinary shares	4,021,080
27/08/2019 I	BVF Partners, L.P., BVF nc. and Mark N. Lampert, BVF Partners OS, Ltd., and Biotechnology Value Trading Fund OS, L.P.	On Market sale of fully paid ordinary shares	AUD 1,932,519.60	715,748 fully paid ordinary shares	715,748
27/08/2019 I	BVF Partners LP, BVF nc. and Mark N. Lampert, and MSI BVF SPV, LLC	On Market sale of fully paid ordinary shares	AUD 863,535.60	319,828 fully paid ordinary shares	319,828

4. Present relevant interests Particulars of each relevant interest of the substantial holder in voting securities after the change are as follows: Holder of relevant interest Registered holder of securities Person entitled to be registered as holder(8) Nature of relevant interest (6) Class and number of securities Person’s votes BVF Partners, L.P. HSBC Custody Nominees (Australia) Limited and BNP Paribas Nominees Pty Ltd Biotechnology Value Fund, L.P, Biotechnology Value Fund II, L.P, Biotechnology Value Trading Fund OS, L.P., MSI BVF SPV, LLC, as per their relevant interests below. Relevant interest arises under section 608(1)(b) of the Corporations Act 2001 (Cth) (Corporations Act) by virtue of BVF Partners, L.P. (i) acting as general partner of, and/or (ii) acting as investment manager of, respectively, the registered holders of the securities, whereby it holds the authority to cast votes in respect of the securities. 13,105,918 fully paid ordinary shares 13,105,918 BVF Inc. and Mark N. Lampert HSBC Custody Nominees (Australia) Limited and BNP Paribas Nominees Pty Ltd Biotechnology Value Fund, L.P, Biotechnology Value Fund II, L.P, Biotechnology Value Trading Fund OS, L.P., MSI BVF SPV, LLC, as per their relevant interests below. Relevant interest arises under section 608(3)(b) of the Corporations Act as each of BVF Inc. and Mark N. Lampert controls BVF Partners, L.P. 13,105,918 fully paid ordinary shares 13,105,918 BVF Partners OS Ltd. HSBC Custody Nominees (Australia) Limited Biotechnology Value Trading Fund OS, L.P. Relevant interest arises under section 608(1)(b) of the Corporations Act by virtue of BVF Partners OS, Ltd. acting as general partner of Biotechnology Value Trading Fund OS, L.P., a registered holder of securities, whereby it holds the authority to cast votes in respect to the securities. 940,439 fully paid ordinary shares 940,439 Biotechnology Value Trading Fund OS, L.P. HSBC Custody Nominees (Australia) Limited Biotechnology Value Trading Fund OS, L.P. Relevant interest arises under section 608(1) of the Corporations Act as beneficial owner of the securities 940,439 fully paid ordinary shares 940,439 Biotechnology Value Fund, L.P. HSBC Custody Nominees (Australia) Limited Biotechnology Value Fund, L.P. Relevant interest arises under section 608(1) of the Corporations Act as beneficial owner of the securities 6,476,972 fully paid ordinary shares 6,476,972 Biotechnology Value Fund II, L.P. HSBC Custody Nominees (Australia) Limited Biotechnology Value Fund II, L.P. Relevant interest arises under section 608(1) of the Corporations Act as beneficial owner of the securities 5,266,877 fully paid ordinary shares 5,266,877	4. Present relevant interests Particulars of each relevant interest of the substantial holder in voting securities after the change are as follows: Holder of relevant interest Registered holder of securities Person entitled to be registered as holder(8) Nature of relevant interest (6) Class and number of securities Person’s votes BVF Partners, L.P. HSBC Custody Nominees (Australia) Limited and BNP Paribas Nominees Pty Ltd Biotechnology Value Fund, L.P, Biotechnology Value Fund II, L.P, Biotechnology Value Trading Fund OS, L.P., MSI BVF SPV, LLC, as per their relevant interests below. Relevant interest arises under section 608(1)(b) of the Corporations Act 2001 (Cth) (Corporations Act) by virtue of BVF Partners, L.P. (i) acting as general partner of, and/or (ii) acting as investment manager of, respectively, the registered holders of the securities, whereby it holds the authority to cast votes in respect of the securities. 13,105,918 fully paid ordinary shares 13,105,918 BVF Inc. and Mark N. Lampert HSBC Custody Nominees (Australia) Limited and BNP Paribas Nominees Pty Ltd Biotechnology Value Fund, L.P, Biotechnology Value Fund II, L.P, Biotechnology Value Trading Fund OS, L.P., MSI BVF SPV, LLC, as per their relevant interests below. Relevant interest arises under section 608(3)(b) of the Corporations Act as each of BVF Inc. and Mark N. Lampert controls BVF Partners, L.P. 13,105,918 fully paid ordinary shares 13,105,918 BVF Partners OS Ltd. HSBC Custody Nominees (Australia) Limited Biotechnology Value Trading Fund OS, L.P. Relevant interest arises under section 608(1)(b) of the Corporations Act by virtue of BVF Partners OS, Ltd. acting as general partner of Biotechnology Value Trading Fund OS, L.P., a registered holder of securities, whereby it holds the authority to cast votes in respect to the securities. 940,439 fully paid ordinary shares 940,439 Biotechnology Value Trading Fund OS, L.P. HSBC Custody Nominees (Australia) Limited Biotechnology Value Trading Fund OS, L.P. Relevant interest arises under section 608(1) of the Corporations Act as beneficial owner of the securities 940,439 fully paid ordinary shares 940,439 Biotechnology Value Fund, L.P. HSBC Custody Nominees (Australia) Limited Biotechnology Value Fund, L.P. Relevant interest arises under section 608(1) of the Corporations Act as beneficial owner of the securities 6,476,972 fully paid ordinary shares 6,476,972 Biotechnology Value Fund II, L.P. HSBC Custody Nominees (Australia) Limited Biotechnology Value Fund II, L.P. Relevant interest arises under section 608(1) of the Corporations Act as beneficial owner of the securities 5,266,877 fully paid ordinary shares 5,266,877	4. Present relevant interests Particulars of each relevant interest of the substantial holder in voting securities after the change are as follows: Holder of relevant interest Registered holder of securities Person entitled to be registered as holder(8) Nature of relevant interest (6) Class and number of securities Person’s votes BVF Partners, L.P. HSBC Custody Nominees (Australia) Limited and BNP Paribas Nominees Pty Ltd Biotechnology Value Fund, L.P, Biotechnology Value Fund II, L.P, Biotechnology Value Trading Fund OS, L.P., MSI BVF SPV, LLC, as per their relevant interests below. Relevant interest arises under section 608(1)(b) of the Corporations Act 2001 (Cth) (Corporations Act) by virtue of BVF Partners, L.P. (i) acting as general partner of, and/or (ii) acting as investment manager of, respectively, the registered holders of the securities, whereby it holds the authority to cast votes in respect of the securities. 13,105,918 fully paid ordinary shares 13,105,918 BVF Inc. and Mark N. Lampert HSBC Custody Nominees (Australia) Limited and BNP Paribas Nominees Pty Ltd Biotechnology Value Fund, L.P, Biotechnology Value Fund II, L.P, Biotechnology Value Trading Fund OS, L.P., MSI BVF SPV, LLC, as per their relevant interests below. Relevant interest arises under section 608(3)(b) of the Corporations Act as each of BVF Inc. and Mark N. Lampert controls BVF Partners, L.P. 13,105,918 fully paid ordinary shares 13,105,918 BVF Partners OS Ltd. HSBC Custody Nominees (Australia) Limited Biotechnology Value Trading Fund OS, L.P. Relevant interest arises under section 608(1)(b) of the Corporations Act by virtue of BVF Partners OS, Ltd. acting as general partner of Biotechnology Value Trading Fund OS, L.P., a registered holder of securities, whereby it holds the authority to cast votes in respect to the securities. 940,439 fully paid ordinary shares 940,439 Biotechnology Value Trading Fund OS, L.P. HSBC Custody Nominees (Australia) Limited Biotechnology Value Trading Fund OS, L.P. Relevant interest arises under section 608(1) of the Corporations Act as beneficial owner of the securities 940,439 fully paid ordinary shares 940,439 Biotechnology Value Fund, L.P. HSBC Custody Nominees (Australia) Limited Biotechnology Value Fund, L.P. Relevant interest arises under section 608(1) of the Corporations Act as beneficial owner of the securities 6,476,972 fully paid ordinary shares 6,476,972 Biotechnology Value Fund II, L.P. HSBC Custody Nominees (Australia) Limited Biotechnology Value Fund II, L.P. Relevant interest arises under section 608(1) of the Corporations Act as beneficial owner of the securities 5,266,877 fully paid ordinary shares 5,266,877	4. Present relevant interests Particulars of each relevant interest of the substantial holder in voting securities after the change are as follows: Holder of relevant interest Registered holder of securities Person entitled to be registered as holder(8) Nature of relevant interest (6) Class and number of securities Person’s votes BVF Partners, L.P. HSBC Custody Nominees (Australia) Limited and BNP Paribas Nominees Pty Ltd Biotechnology Value Fund, L.P, Biotechnology Value Fund II, L.P, Biotechnology Value Trading Fund OS, L.P., MSI BVF SPV, LLC, as per their relevant interests below. Relevant interest arises under section 608(1)(b) of the Corporations Act 2001 (Cth) (Corporations Act) by virtue of BVF Partners, L.P. (i) acting as general partner of, and/or (ii) acting as investment manager of, respectively, the registered holders of the securities, whereby it holds the authority to cast votes in respect of the securities. 13,105,918 fully paid ordinary shares 13,105,918 BVF Inc. and Mark N. Lampert HSBC Custody Nominees (Australia) Limited and BNP Paribas Nominees Pty Ltd Biotechnology Value Fund, L.P, Biotechnology Value Fund II, L.P, Biotechnology Value Trading Fund OS, L.P., MSI BVF SPV, LLC, as per their relevant interests below. Relevant interest arises under section 608(3)(b) of the Corporations Act as each of BVF Inc. and Mark N. Lampert controls BVF Partners, L.P. 13,105,918 fully paid ordinary shares 13,105,918 BVF Partners OS Ltd. HSBC Custody Nominees (Australia) Limited Biotechnology Value Trading Fund OS, L.P. Relevant interest arises under section 608(1)(b) of the Corporations Act by virtue of BVF Partners OS, Ltd. acting as general partner of Biotechnology Value Trading Fund OS, L.P., a registered holder of securities, whereby it holds the authority to cast votes in respect to the securities. 940,439 fully paid ordinary shares 940,439 Biotechnology Value Trading Fund OS, L.P. HSBC Custody Nominees (Australia) Limited Biotechnology Value Trading Fund OS, L.P. Relevant interest arises under section 608(1) of the Corporations Act as beneficial owner of the securities 940,439 fully paid ordinary shares 940,439 Biotechnology Value Fund, L.P. HSBC Custody Nominees (Australia) Limited Biotechnology Value Fund, L.P. Relevant interest arises under section 608(1) of the Corporations Act as beneficial owner of the securities 6,476,972 fully paid ordinary shares 6,476,972 Biotechnology Value Fund II, L.P. HSBC Custody Nominees (Australia) Limited Biotechnology Value Fund II, L.P. Relevant interest arises under section 608(1) of the Corporations Act as beneficial owner of the securities 5,266,877 fully paid ordinary shares 5,266,877	4. Present relevant interests Particulars of each relevant interest of the substantial holder in voting securities after the change are as follows: Holder of relevant interest Registered holder of securities Person entitled to be registered as holder(8) Nature of relevant interest (6) Class and number of securities Person’s votes BVF Partners, L.P. HSBC Custody Nominees (Australia) Limited and BNP Paribas Nominees Pty Ltd Biotechnology Value Fund, L.P, Biotechnology Value Fund II, L.P, Biotechnology Value Trading Fund OS, L.P., MSI BVF SPV, LLC, as per their relevant interests below. Relevant interest arises under section 608(1)(b) of the Corporations Act 2001 (Cth) (Corporations Act) by virtue of BVF Partners, L.P. (i) acting as general partner of, and/or (ii) acting as investment manager of, respectively, the registered holders of the securities, whereby it holds the authority to cast votes in respect of the securities. 13,105,918 fully paid ordinary shares 13,105,918 BVF Inc. and Mark N. Lampert HSBC Custody Nominees (Australia) Limited and BNP Paribas Nominees Pty Ltd Biotechnology Value Fund, L.P, Biotechnology Value Fund II, L.P, Biotechnology Value Trading Fund OS, L.P., MSI BVF SPV, LLC, as per their relevant interests below. Relevant interest arises under section 608(3)(b) of the Corporations Act as each of BVF Inc. and Mark N. Lampert controls BVF Partners, L.P. 13,105,918 fully paid ordinary shares 13,105,918 BVF Partners OS Ltd. HSBC Custody Nominees (Australia) Limited Biotechnology Value Trading Fund OS, L.P. Relevant interest arises under section 608(1)(b) of the Corporations Act by virtue of BVF Partners OS, Ltd. acting as general partner of Biotechnology Value Trading Fund OS, L.P., a registered holder of securities, whereby it holds the authority to cast votes in respect to the securities. 940,439 fully paid ordinary shares 940,439 Biotechnology Value Trading Fund OS, L.P. HSBC Custody Nominees (Australia) Limited Biotechnology Value Trading Fund OS, L.P. Relevant interest arises under section 608(1) of the Corporations Act as beneficial owner of the securities 940,439 fully paid ordinary shares 940,439 Biotechnology Value Fund, L.P. HSBC Custody Nominees (Australia) Limited Biotechnology Value Fund, L.P. Relevant interest arises under section 608(1) of the Corporations Act as beneficial owner of the securities 6,476,972 fully paid ordinary shares 6,476,972 Biotechnology Value Fund II, L.P. HSBC Custody Nominees (Australia) Limited Biotechnology Value Fund II, L.P. Relevant interest arises under section 608(1) of the Corporations Act as beneficial owner of the securities 5,266,877 fully paid ordinary shares 5,266,877	4. Present relevant interests Particulars of each relevant interest of the substantial holder in voting securities after the change are as follows: Holder of relevant interest Registered holder of securities Person entitled to be registered as holder(8) Nature of relevant interest (6) Class and number of securities Person’s votes BVF Partners, L.P. HSBC Custody Nominees (Australia) Limited and BNP Paribas Nominees Pty Ltd Biotechnology Value Fund, L.P, Biotechnology Value Fund II, L.P, Biotechnology Value Trading Fund OS, L.P., MSI BVF SPV, LLC, as per their relevant interests below. Relevant interest arises under section 608(1)(b) of the Corporations Act 2001 (Cth) (Corporations Act) by virtue of BVF Partners, L.P. (i) acting as general partner of, and/or (ii) acting as investment manager of, respectively, the registered holders of the securities, whereby it holds the authority to cast votes in respect of the securities. 13,105,918 fully paid ordinary shares 13,105,918 BVF Inc. and Mark N. Lampert HSBC Custody Nominees (Australia) Limited and BNP Paribas Nominees Pty Ltd Biotechnology Value Fund, L.P, Biotechnology Value Fund II, L.P, Biotechnology Value Trading Fund OS, L.P., MSI BVF SPV, LLC, as per their relevant interests below. Relevant interest arises under section 608(3)(b) of the Corporations Act as each of BVF Inc. and Mark N. Lampert controls BVF Partners, L.P. 13,105,918 fully paid ordinary shares 13,105,918 BVF Partners OS Ltd. HSBC Custody Nominees (Australia) Limited Biotechnology Value Trading Fund OS, L.P. Relevant interest arises under section 608(1)(b) of the Corporations Act by virtue of BVF Partners OS, Ltd. acting as general partner of Biotechnology Value Trading Fund OS, L.P., a registered holder of securities, whereby it holds the authority to cast votes in respect to the securities. 940,439 fully paid ordinary shares 940,439 Biotechnology Value Trading Fund OS, L.P. HSBC Custody Nominees (Australia) Limited Biotechnology Value Trading Fund OS, L.P. Relevant interest arises under section 608(1) of the Corporations Act as beneficial owner of the securities 940,439 fully paid ordinary shares 940,439 Biotechnology Value Fund, L.P. HSBC Custody Nominees (Australia) Limited Biotechnology Value Fund, L.P. Relevant interest arises under section 608(1) of the Corporations Act as beneficial owner of the securities 6,476,972 fully paid ordinary shares 6,476,972 Biotechnology Value Fund II, L.P. HSBC Custody Nominees (Australia) Limited Biotechnology Value Fund II, L.P. Relevant interest arises under section 608(1) of the Corporations Act as beneficial owner of the securities 5,266,877 fully paid ordinary shares 5,266,877	4. Present relevant interests Particulars of each relevant interest of the substantial holder in voting securities after the change are as follows: Holder of relevant interest Registered holder of securities Person entitled to be registered as holder(8) Nature of relevant interest (6) Class and number of securities Person’s votes BVF Partners, L.P. HSBC Custody Nominees (Australia) Limited and BNP Paribas Nominees Pty Ltd Biotechnology Value Fund, L.P, Biotechnology Value Fund II, L.P, Biotechnology Value Trading Fund OS, L.P., MSI BVF SPV, LLC, as per their relevant interests below. Relevant interest arises under section 608(1)(b) of the Corporations Act 2001 (Cth) (Corporations Act) by virtue of BVF Partners, L.P. (i) acting as general partner of, and/or (ii) acting as investment manager of, respectively, the registered holders of the securities, whereby it holds the authority to cast votes in respect of the securities. 13,105,918 fully paid ordinary shares 13,105,918 BVF Inc. and Mark N. Lampert HSBC Custody Nominees (Australia) Limited and BNP Paribas Nominees Pty Ltd Biotechnology Value Fund, L.P, Biotechnology Value Fund II, L.P, Biotechnology Value Trading Fund OS, L.P., MSI BVF SPV, LLC, as per their relevant interests below. Relevant interest arises under section 608(3)(b) of the Corporations Act as each of BVF Inc. and Mark N. Lampert controls BVF Partners, L.P. 13,105,918 fully paid ordinary shares 13,105,918 BVF Partners OS Ltd. HSBC Custody Nominees (Australia) Limited Biotechnology Value Trading Fund OS, L.P. Relevant interest arises under section 608(1)(b) of the Corporations Act by virtue of BVF Partners OS, Ltd. acting as general partner of Biotechnology Value Trading Fund OS, L.P., a registered holder of securities, whereby it holds the authority to cast votes in respect to the securities. 940,439 fully paid ordinary shares 940,439 Biotechnology Value Trading Fund OS, L.P. HSBC Custody Nominees (Australia) Limited Biotechnology Value Trading Fund OS, L.P. Relevant interest arises under section 608(1) of the Corporations Act as beneficial owner of the securities 940,439 fully paid ordinary shares 940,439 Biotechnology Value Fund, L.P. HSBC Custody Nominees (Australia) Limited Biotechnology Value Fund, L.P. Relevant interest arises under section 608(1) of the Corporations Act as beneficial owner of the securities 6,476,972 fully paid ordinary shares 6,476,972 Biotechnology Value Fund II, L.P. HSBC Custody Nominees (Australia) Limited Biotechnology Value Fund II, L.P. Relevant interest arises under section 608(1) of the Corporations Act as beneficial owner of the securities 5,266,877 fully paid ordinary shares 5,266,877
	Holder of relevant interest	Registered holder of securities	Person entitled to be registered as holder(8)	Nature of relevant interest (6)	Class and number of securities	Person’s votes
	BVF Partners, L.P.	HSBC Custody Nominees (Australia) Limited and BNP Paribas Nominees Pty Ltd	Biotechnology Value Fund, L.P, Biotechnology Value Fund II, L.P, Biotechnology Value Trading Fund OS, L.P., MSI BVF SPV, LLC, as per their relevant interests below.	Relevant interest arises under section 608(1)(b) of the Corporations Act 2001 (Cth) (Corporations Act) by virtue of BVF Partners, L.P. (i) acting as general partner of, and/or (ii) acting as investment manager of, respectively, the registered holders of the securities, whereby it holds the authority to cast votes in respect of the securities.	13,105,918 fully paid ordinary shares	13,105,918
	BVF Inc. and Mark N. Lampert	HSBC Custody Nominees (Australia) Limited and BNP Paribas Nominees Pty Ltd	Biotechnology Value Fund, L.P, Biotechnology Value Fund II, L.P, Biotechnology Value Trading Fund OS, L.P., MSI BVF SPV, LLC, as per their relevant interests below.	Relevant interest arises under section 608(3)(b) of the Corporations Act as each of BVF Inc. and Mark N. Lampert controls BVF Partners, L.P.	13,105,918 fully paid ordinary shares	13,105,918
	BVF Partners OS Ltd.	HSBC Custody Nominees (Australia) Limited	Biotechnology Value Trading Fund OS, L.P.	Relevant interest arises under section 608(1)(b) of the Corporations Act by virtue of BVF Partners OS, Ltd. acting as general partner of Biotechnology Value Trading Fund OS, L.P., a registered holder of securities, whereby it holds the authority to cast votes in respect to the securities.	940,439 fully paid ordinary shares	940,439
	Biotechnology Value Trading Fund OS, L.P.	HSBC Custody Nominees (Australia) Limited	Biotechnology Value Trading Fund OS, L.P.	Relevant interest arises under section 608(1) of the Corporations Act as beneficial owner of the securities	940,439 fully paid ordinary shares	940,439
	Biotechnology Value Fund, L.P.	HSBC Custody Nominees (Australia) Limited	Biotechnology Value Fund, L.P.	Relevant interest arises under section 608(1) of the Corporations Act as beneficial owner of the securities	6,476,972 fully paid ordinary shares	6,476,972
	Biotechnology Value Fund II, L.P.	HSBC Custody Nominees (Australia) Limited	Biotechnology Value Fund II, L.P.	Relevant interest arises under section 608(1) of the Corporations Act as beneficial owner of the securities	5,266,877 fully paid ordinary shares	5,266,877

MSI BVF SPV, LLC	BNP Paribas Nominees Pty Ltd	MSI BVF SPV, LLC	Relevant interest arises under section 608(1) of the Corporations Act as beneficial owner of the securities	421,630 fully paid ordinary shares	421,630

5. Changes in association

The persons who have become associates (2) of, ceased to be associates of, or have changed the nature of their association (9) with, the substantial holder in relation to voting interests in the company or scheme are as follows:

Name and ACN/ARSN (if applicable)	Nature of association
Not applicable	Not applicable

6. Addresses

The addresses of persons named in this form are as follows:

Name	Address
BVF Partners LP Biotechnology Value Fund, L.P. Biotechnology Value Fund II, L.P. BVF Inc.	44 Montgomery, 40thFloor San Francisco, California 94104 United States of America
BVF Partners OS, Ltd Biotechnology Value Trading Fund OS, L.P.	PO Box 309 Ugland House Grand Cayman, KY1-1104 Cayman Islands
MSI BVF SPV, LLC	c/o Magnitude Capital, L.L.C. 601 Lexington Avenue, 59thFloor New York, NY 10022
Mark N. Lampert	c/o BVF Inc 44 Montgomery, 40thFloor San Francisco, California 94104 United States of America

Signature
		BVF Partners LP BY BVF Inc., its general partner, BY Mark N. Lampert,		General Partner and
	print name	President	capacity	Attorney-in-Fact for the
				Substantial Holders
	sign here		date	29/08/2019